In this study, an in vitro ligation method was developed to assemble a full-length infectious cDNA clone of the Zika virus (ZIKV). Four contiguous cDNA subclones covering the complete ZIKV genome were constructed with unique BglI restriction sites at the ends of each fragment. The BglI restriction sites only allow in vitro ligation to happen between interconnecting restriction sites from adjacent cDNA fragments, resulting in an intact full-length cDNA of ZIKV. RNA transcripts derived from the full-length cDNA were infectious. The recombinant virus replicated as efficiently as the wild-type virus with similar growth kinetics and plaque morphologies in Vero and C6/36 cells. Both viruses were inhibited by NITD008 treatment. This in vitro ligation method will facilitate manipulation of the viral genome through genetic modifications of four separated subclones of ZIKV for the rapid and rational development of candidate vaccines and viral replication study.
Zika virus (ZIKV) belongs to the Flavivirus genus of the family Flaviviridae which includes many important human pathogens, such as Dengue virus (DENV), yellow fever virus (YFV), West Nile virus (WNV) and tick-borne encephalitis virus (TBEV). ZIKV was first isolated in 1947 from monkey in Uganda and remained as a neglected pathogen until 2007 when a large epidemic emerged in Micronesia [1] . Now ZIKV has become a big burden on public health with increasing evidence of its link with microcephaly and Guillain-Barr e syndrome [2] [3] [4] . No approved vaccines or efficient antivirals are available against its infection.
ZIKV is a positive single-stranded RNA virus. The viral genome is about 11 000 nucleotides containing a single ORF flanked by 5¢ UTR and 3¢ UTR. The ORF encodes a large polyprotein which is cleaved by host and viral proteases into three structural (capsid, precursor membrane/membrane and envelope) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) proteins [5] . The reverse genetic approach of ZIKV will help to either study viral pathogenesis or develop antiviral therapeutics [6] . Different strategies have been explored to develop a ZIKV reverse genetic system for Asian and African lineages [6] [7] [8] [9] [10] [11] [12] . The first infectious cDNA clone of ZIKV in the low-copy plasmid was reported using a clinical isolate of the Asian lineage [9] . Then Gibson assembly was used to create the full-length ZIKV infectious clone (isolate from Puerto Rico, PRVABC59) from a two-part cDNA clone [7] . The method of intron insertion within the viral genome sequence was applied to generate two ZIKV plasmid cDNAs containing a cytomegalovirus (CMV) promoter to rescue recombinant viruses of prototype 1947 Uganda MR766 ZIKV [10] and ZIKV isolated from the 2015 epidemic in Brazil [8] , respectively. Using the bacterium-free infectious subgenomic amplicon (ISA) method, reverse genetic systems for both Asian and African ZIKV were developed [12] , and a similar strategy was also developed for ZIKV strain MR766 infectious clone and eGFP reporter viruses [11] .
In this study, the strain SZ-WIV01 (KU963796) of ZIKV [13] rescued from Vero cells was used as the parental virus to construct the viral infectious clone. SZ-WIV01 belongs to Asian lineage [13] . The genomic RNA of ZIKV was extracted with QIAamp Viral RNA Mini Kit (Qiagen) from 140 µl of the culture medium from infected Vero cells. Initially, we tried to construct the ZIKV infectious cDNA clone by engineering the complete viral genome cDNA sequence into one low-copy plasmid. It turned out that the recombinant plasmids were not stable, generating different mutations in the viral genome during the screening of the infectious cDNA clone. We then explored in vitro ligation strategy [14] [15] [16] [17] for clone construction. Using the extracted viral RNA as a template, four cDNA fragments (F1, F2, F3 and F4) covering the complete genome were amplified through a reverse transcriptase-PCR (RT-PCR) with four pairs of primers (Table S1 , available in the online Supplementary Material) containing different BglI restriction sites. BglI is a restriction endonuclease that recognizes the sequence (GCCNNNN#NGGC) and cleaves the DNA to produce different individual fragment ends from the sticky ends of different cut sites with 3¢-overhangs. Using the nature of BglI-overhang, all four cDNA fragments can be directionally assembled into a genome-length cDNA with unique BglI restriction sites through in vitro ligation (Fig. 1) . F1 contained the 5¢ end to the nucleotide position 3948, and T7 promoter with an additional G for efficient transcription was inserted before the 5¢ end of the viral sequence [18] . F2 and F3 contained the sequence from nucleotide positions 3948-6591 and 6591-8045, respectively. F4 contained the sequence from nucleotide position 8045 to the 3¢ end with a downstream hepatitis delta virus ribozyme (HDVr) sequence for the production of the authentic 3¢ end. The pMD18T vector was then used for the subclones of F2/F3/F4 fragments except an alternative low copy-number vector, pACYC177, was used for the subclone of the F1 fragment that was genetically unstable or/and toxic to Escherichia coli. Specifically, F1 was cloned into pACYC177 at KpnI and XhoI sites, resulting in the subclone pACYC-F1. F2, F3 and F4 were cloned into the pMD18T vector, yielding three constructs called pMD18T-F2, pMD18T-F3 and pMD18T-F4. All subclones were validated by sequencing.
To build a full-length ZIKV cDNA, about 10 µg of each subclone plasmid was first digested with a BglI restriction enzyme. The resulting F1, F2, F3 and F4 cDNA fragments were then separated in 1 % agarose gels and purified with Gel Extraction Kit (QIAgen). For in vitro ligation, equimolar amounts of each purified fragment comprising a total of 4.7 µg were mixed with 20 µl of T4 DNA ligase in a 200 µl ligation reaction. The ligated full-length cDNA products (~11 kb) were purified with a phenol-chloroform method and suspended in nuclease-free H 2 O. One µg of purified full-length cDNA was then used as a template for in vitro transcription with T7 mMESSAGE mMACHINE kit (Ambion) to produce recombinant viral RNA. Approximately 45 µg of RNA was yielded from the transcription system.
The in vitro transcribed ZIKV recombinant RNA was electroporated into BHK-21 cells. Briefly, 20 µg RNA was electroporated into 8Â10 6 BHK-21 cells in 0.8 ml of ice cold PBS, pH 7.5, in a 4 mm cuvette with the GenePulser apparatus (Bio-Rad) at 0.85 kV and 25 µF, pulsing three times with 3 s intervals. After a 10 min recovery at room temperature, cells were mixed with pre-warmed DMEM containing 10 % FBS and incubated in a T-75 flask at 37 C with 5 % CO 2 . First, an immunofluorescence assay (IFA) was performed to examine viral protein expression with pan-flavivirus envelope protein antibody 4G2 that was kindly provided by Dr Cheng-feng Qin (Beijing Institute of Microbiology and Epidemiology, PR China). As shown in Fig. 2(a) , increasing amounts of IFA-positive cells were observed from 48 to 96 h post transfection (h p.t.), demonstrating that the transcribed RNA was replicative and produced infectious viruses. Then the culture medium derived from transfected cells at 96 h p.t. was used to infect naive Vero cells, and the apparent cytopathogenic effect (CPE) appeared after 72 h post infection (h p.i.) in comparison with mock-infected Vero cells (Fig. 2b) , providing further evidence that the recombinant viruses were infectious. Additionally, a 1.5 Kb RT-PCR product was obtained from the recombinant virus using a pair of primer-spanning viral E-NS2A regions (ZIKV-2472-F/ZIKV-3867-R; Table S1 ) that were the same size as the parental viruses (Fig. 2c) . To distinguish the recombinant virus from the parental virus, two synonymous mutations were engineered into BglI sites at nucleotide positions 6596 (G to A) and 8411 (G to A) (Fig. 1a) . Viral genome sequencing showed that engineered mutations were found in recombinant viruses (Fig. 2d) . Overall, our results demonstrated that infectious recombinant ZIKV was produced from BHK-21 cells transfected with transcribed ZIKV RNA.
The phenotypes of recombinant and parental ZIKV were then compared by plaque assay. Vero cells were seeded in 24-well plates with a density of 1.0Â10 5 cells well À1 and incubated at 37 C overnight. Virus-containing culture fluids were tenfold serially diluted six times in DMEM. For each dilution, a 100 µl sample was added to Vero cell monolayers per well. After 1 h of incubation at 37 C with 5 % CO 2 , the culture was discarded, and the fresh medium mixed with 2 % methyl cellulose was added to each well. Following the incubation at 37 C for 4 days, the layer was removed, and cells were fixed with 3.7 % formaldehyde and stained with 1 % crystal violet. The visible plaques were counted and p.f.u. per ml were calculated. Similar plaque morphologies were observed between these two viruses (Fig. 3a) . Their viral growth curves were also indistinguishable in either Vero or C6/36 cells (Fig. 3b, c) at a m.o.i. of 0.1. Additionally, the recombinant and parental ZIKVinfected Vero cells (at m.o.i. 0.1) were treated with different concentrations of NITD008 (a known nucleoside inhibitor of flaviviruses [19] ). Cell cultures were collected at 48 h p.i. and viral titres were determined by plaque assay. Similar viral growth inhibitions were also observed for both viruses at different concentrations of NITD008, which was synthesized as reported previously [19] (Fig. 3d) , and the CC50 of NITD008 was 119.97 µM in Vero cells based on our previous study [20] . In this study, EC50 were 0.51 and 0.55 µM for parental and recombinant viruses, respectively. These results demonstrated that the recombinant and parental viruses are similar in cell culture study.
In this study, we provided an alternative method to construct the infectious clone for ZIKV. Our reverse genetic system of ZIKV will be a good tool to study viral replication through mutagenesis analysis. The specific mutations (such as deletions, insertions or point mutations) could be easily introduced into a defined position of each subclone instead of manipulating the full-length infectious clone. The modified subclone can be reassembled together with the remaining unmodified fragments for the production of recombinant mutant viruses. 
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